Literature DB >> 22648773

Animal models for prenatal gene therapy: choosing the right model.

Vedanta Mehta1, Donald Peebles, Anna L David.   

Abstract

Testing in animal models is an essential requirement during development of prenatal gene therapy for -clinical application. Some information can be derived from cell lines or cultured fetal cells, such as the efficiency of gene transfer and the vector dose that might be required. Fetal tissues can also be maintained in culture for short periods of time and transduced ex vivo. Ultimately, however, the use of animals is unavoidable since in vivo experiments allow the length and level of transgene expression to be measured, and provide an assessment of the effect of the delivery procedure and the gene therapy on fetal and neonatal development. The choice of animal model is determined by the nature of the disease and characteristics of the animal, such as its size, lifespan, and immunology, the number of fetuses and their development, parturition, and the length of gestation and the placentation. The availability of a disease model is also critical. In this chapter, we discuss the various animal models that can be used and consider how their characteristics can affect the results obtained. The projection to human application and the regulatory hurdles are also presented.

Entities:  

Mesh:

Year:  2012        PMID: 22648773     DOI: 10.1007/978-1-61779-873-3_9

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  3 in total

1.  Strategies for intra-amniotic administration of fetal therapy in a rabbit model of intrauterine growth restriction.

Authors:  Mari Kinoshita; Fàtima Crispi; Carla Loreiro; Eduard Gratacós; Míriam Illa; Mònica Zamora
Journal:  Exp Biol Med (Maywood)       Date:  2021-04-01

2.  Orthologs of human disease associated genes and RNAi analysis of silencing insulin receptor gene in Bombyx mori.

Authors:  Zan Zhang; Xiaolu Teng; Maohua Chen; Fei Li
Journal:  Int J Mol Sci       Date:  2014-10-09       Impact factor: 5.923

3.  In utero therapy for congenital disorders using amniotic fluid stem cells.

Authors:  Durrgah L Ramachandra; Steven S W Shaw; Panicos Shangaris; Stavros Loukogeorgakis; Pascale V Guillot; Paolo De Coppi; Anna L David
Journal:  Front Pharmacol       Date:  2014-12-19       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.